Hear how HTG Molecular is committed to collaborating with our investigators around the globe to address key diagnostic and therapeutic questions that can eventually be translated to empower precision medicine at the local level.
As an example, at the ASCO 2019 Clinical Science Symposium, Dr. William from M.D. Anderson and Hospital BP in Sao Paulo Brazil presented an interesting body of work around the molecular landscape of oral neoplasias and the risk of progression to malignancy.
Our next-generation sequencing (NGS)-adapted chemistry and instrument platforms automate sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets from samples a fraction of the size required by competitive technologies, enabling customers to do more molecular profiling with less sample.Learn More
Hosted by HTG, the event featured a presentation by Adam Brufsky, MD, PhD (Co-Director, Comprehensive Breast Cancer Center and Medical Director, Woman’s Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh PA), who discussed the current challenges in diagnosing breast cancer and unmet medical needs and optimizing treatment. Dr. Brufsky answered questions at the conclusion of the event.
HTG Molecular Diagnostics' management team provided an update of their development plan to build a comprehensive breast cancer diagnostic platform. This plan showcased the product roadmap and milestones demonstrating the company’s progresses towards assays that can help clinicians improve the care of cancer patients.
Page last updated April 27, 2020